Challenges in the treatment of chronic hepatitis C in the HIV/HCV-coinfected patient

References

• Alter MJ. Epidemiology of viral hepatitis and HIV co-infection. J. Hepatol. 44(Suppl. 1), S6–S9 (2006).
   PubMed Web of Science ®Google Scholar
• Sherman KE, Rouster SD, Chung RT, Rajicic N. Hepatitis C Virus prevalence among patients infected with Human Immunodeficiency Virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group. Clin. Infect. Dis. 34(6), 831–837 (2002).
   PubMed Web of Science ®Google Scholar
• Staples CTJr, Rimland D, Dudas D. Hepatitis C in the HIV (human immunodeficiency virus) Atlanta V.A. (Veterans Affairs Medical Center) Cohort Study (HAVACS): the effect of coinfection on survival. Clin. Infect. Dis. 29(1), 150–154 (1999).
   PubMed Web of Science ®Google Scholar
• Danta M, Brown D, Bhagani S et al. HIV and Acute HCV (HAAC) group. Recent epidemic of acute hepatitis C virus in HIV-positive men who have sex with men linked to high-risk sexual behaviours. AIDS 21(8), 983–991 (2007).
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). Sexual transmission of hepatitis C virus among HIV-infected men who have sex with men – New York City, 2005–2010. MMWR Morb. Mortal. Wkly Rep. 60(28), 945–950 (2011).
   PubMedGoogle Scholar
• Tohme RA, Holmberg SD. Is sexual contact a major mode of hepatitis C virus transmission? Hepatology 52(4), 1497–1505 (2010).
   PubMed Web of Science ®Google Scholar
• van de Laar T, Pybus O, Bruisten S, et al. Evidence of a large, international network of HCV transmission in HIV-positive men who have sex with men. Gastroenterology. 136, 1609–1617 (2009).
   PubMed Web of Science ®Google Scholar
• Chen TY, Ding EL, Seage Iii GR, Kim AY. Meta-analysis: increased mortality associated with hepatitis C in HIV-infected persons is unrelated to HIV disease progression. Clin. Infect. Dis. 49(10), 1605–1615 (2009).
   PubMed Web of Science ®Google Scholar
• Thomas DL, Astemborski J, Rai RM et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA 284(4), 450–456 (2000).
   PubMed Web of Science ®Google Scholar
• Thomas DL, Astemborski J, Vlahov D et al. Determinants of the quantity of hepatitis C virus RNA. J. Infect. Dis. 181(3), 844–851 (2000).
   PubMed Web of Science ®Google Scholar
• Graham CS, Baden LR, Yu E et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin. Infect. Dis. 33(4), 562–569 (2001).
   PubMed Web of Science ®Google Scholar
• Goedert JJ, Eyster ME, Lederman MM et al. End-stage liver disease in persons with hemophilia and transfusion-associated infections. Blood 100(5), 1584–1589 (2002).
   PubMed Web of Science ®Google Scholar
• Sulkowski MS, Benhamou Y. Therapeutic issues in HIV/HCV-coinfected patients. J. Viral Hepat. 14(6), 371–386 (2007).
   PubMed Web of Science ®Google Scholar
• Torriani FJ, Rodriguez-Torres M, Rockstroh JK et al. APRICOT Study Group. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N. Engl. J. Med. 351(5), 438–450 (2004).
   PubMed Web of Science ®Google Scholar
• Hadziyannis SJ, Sette H Jr, Morgan TR et al. PEGASYS International Study Group. Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann. Intern. Med. 140(5), 346–355 (2004).
   PubMed Web of Science ®Google Scholar
• Laguno M, Murillas J, Blanco JL et al. Peginterferon α-2b plus ribavirin compared with interferon α-2b plus ribavirin for treatment of HIV/HCV co-infected patients. AIDS 18(13), F27–F36 (2004).
   Google Scholar
• McLaren M, Garber G, Cooper C. Barriers to hepatitis C virus treatment in a Canadian HIV-hepatitis C virus coinfection tertiary care clinic. Can. J. Gastroenterol. 22(2), 133–137 (2008).
   PubMed Web of Science ®Google Scholar
• Butt AA, Justice AC, Skanderson M, Good C, Kwoh CK. Rates and predictors of hepatitis C virus treatment in HCV-HIV-coinfected subjects. Aliment. Pharmacol. Ther. 24(4), 585–591 (2006).
   PubMed Web of Science ®Google Scholar
• Nunes D, Saitz R, Libman H, Cheng DM, Vidaver J, Samet JH. Barriers to treatment of hepatitis C in HIV/HCV-coinfected adults with alcohol problems. Alcohol. Clin. Exp. Res. 30(9), 1520–1526 (2006).
   PubMed Web of Science ®Google Scholar
• Bräu N, Salvatore M, Ríos-Bedoya CF et al. Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy. J. Hepatol. 44(1), 47–55 (2006).
   PubMed Web of Science ®Google Scholar
• Marcellin F, Préau M, Ravaux I, Dellamonica P, Spire B, Carrieri MP. Self-reported fatigue and depressive symptoms as main indicators of the quality of life (QOL) of patients living with HIV and Hepatitis C: implications for clinical management and future research. HIV Clin. Trials 8(5), 320–327 (2007).
   PubMed Web of Science ®Google Scholar
• Thomas DL, Leoutsakas D, Zabransky T, Kumar MS. Hepatitis C in HIV-infected individuals: cure and control, right now. J. Int. AIDS Soc. 14, 22 (2011).
   PubMedGoogle Scholar
• Sulkowski MS, Mehta SH, Torbenson MS et al. Rapid fibrosis progression among HIV/hepatitis C virus-co-infected adults. AIDS 21(16), 2209–2216 (2007).
   PubMed Web of Science ®Google Scholar
• Rodríguez-Torres M, Rodríguez-Orengo JF, Ríos-Bedoya CF et al. Effect of hepatitis C virus treatment in fibrosis progression rate (FPR) and time to cirrhosis (TTC) in patients co-infected with human immunodeficiency virus: a paired liver biopsy study. J. Hepatol. 46(4), 613–619 (2007).
   PubMed Web of Science ®Google Scholar
• Carrat F, Bani-Sadr F, Pol S et al. ANRS HCO2 RIBAVIC Study Team. Pegylated interferon alfa-2b vs standard interferon α-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 292(23), 2839–2848 (2004).
   PubMed Web of Science ®Google Scholar
• Chung RT, Andersen J, Volberding P et al. AIDS Clinical Trials Group A5071 Study Team. Peginterferon α-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N. Engl. J. Med. 351(5), 451–459 (2004).
   PubMed Web of Science ®Google Scholar
• Labarga P, Vispo E, Barreiro P et al. Rate and predictors of success in the retreatment of chronic hepatitis C virus in HIV/hepatitis C Virus coinfected patients with prior nonresponse or relapse. J. Acquir. Immune Defic. Syndr. 53(3), 364–368 (2010).
   PubMedGoogle Scholar
• Berenguer J, Alvarez-Pellicer J, Martín PM et al. GESIDA3603/5607 Study Group. Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology 50(2), 407–413 (2009).
   PubMed Web of Science ®Google Scholar
• Labarga P, Soriano V, Vispo ME et al. Hepatotoxicity of antiretroviral drugs is reduced after successful treatment of chronic hepatitis C in HIV-infected patients. J. Infect. Dis. 196(5), 670–676 (2007).
   PubMed Web of Science ®Google Scholar
• Soriano V, Puoti M, Sulkowski M et al. Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel. AIDS 21(9), 1073–1089 (2007).
   PubMed Web of Science ®Google Scholar
• Thompson MA, Aberg JA, Cahn P et al. International AIDS Society-USA. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society – USA panel. JAMA 304(3), 321–333 (2010).
   PubMed Web of Science ®Google Scholar
• Sulkowski MS. Management of hepatic complications in HIV-infected persons. J. Infect. Dis. 197(Suppl. 3), S279–S293 (2008).
   PubMed Web of Science ®Google Scholar
• Pascual-Pareja JF, Caminoa A, Larrauri C et al. HAART is associated with lower hepatic necroinflammatory activity in HIV-hepatitis C virus-coinfected patients with CD4 cell count of more than 350 cells/microl at the time of liver biopsy. AIDS 23(8), 971–975 (2009).
   PubMedGoogle Scholar
• Moodie EE, Pant Pai N, Klein MB. Is antiretroviral therapy causing long-term liver damage? A comparative analysis of HIV-mono-infected and HIV/hepatitis C co-infected cohorts. PLoS One 4(2), e4517 (2009).
   Google Scholar
• Sulkowski MS. Viral hepatitis and HIV coinfection. J. Hepatol. 48(2), 353–367 (2008).
   PubMed Web of Science ®Google Scholar
• Maida I, Garcia-Gasco P, Sotgiu G et al. Antiretroviral-associated portal hypertension: a new clinical condition? Prevalence, predictors and outcome. Antivir. Ther. (Lond.) 13(1), 103–107 (2008).
   PubMed Web of Science ®Google Scholar
• VispoE, Barreiro P, Pineda JA et al. Low response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C treated with abacavir. Antivir. Ther. 13(3), 429–437 (2008).
   PubMed Web of Science ®Google Scholar
• SolasC, Pambrun E, Winnock M et al.; The ANRS CO-13 HEPAVIH Study Group. Ribavirin and abacavir drug interaction in HIV-HCV coinfected patients: fact or fiction? AIDS doi:10.1097/QAD.0b013e32835763a4 (2012) (Epub ahead of print).
   PubMedGoogle Scholar
• Venhoff N, Setzer B, Melkaoui K, Walker UA. Mitochondrial toxicity of tenofovir, emtricitabine and abacavir alone and in combination with additional nucleoside reverse transcriptase inhibitors. Antivir. Ther. (Lond.) 12(7), 1075–1085 (2007).
   PubMed Web of Science ®Google Scholar
• de Mendoza C, Martin-Carbonero L, Barreiro P et al. Mitochondrial DNA depletion in HIV-infected patients with chronic hepatitis C and effect of pegylated interferon plus ribavirin therapy. AIDS 21(5), 583–588 (2007).
   PubMed Web of Science ®Google Scholar
• Reiberger T, Kosi L, Maresch J et al. Mitochondrial toxicity is associated with virological response in patients with HIV and hepatitis C virus coinfection treated with ribavirin and highly active antiretroviral therapy. J. Infect. Dis. 202(1), 156–160 (2010).
   PubMedGoogle Scholar
• Sherman KE, Rouster SD, Stanford S et al. AIDS Clinical Trials Group 5071 Study Team. Hepatitis C virus (HCV) quasispecies complexity and selection in HCV/HIV-coinfected subjects treated with interferon-based regimens. J. Infect. Dis. 201(5), 712–719 (2010).
   PubMedGoogle Scholar
• Martin-Carbonero L, Nuñez M, Mariño A et al. Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C. AIDS 22(1), 15–21 (2008).
   PubMed Web of Science ®Google Scholar
• Opravil M, Sasadeusz J, Cooper DA et al. Effect of baseline CD4 cell count on the efficacy and safety of peginterferon Alfa-2a (40KD) plus ribavirin in patients with HIV/hepatitis C virus coinfection. J. Acquir. Immune Defic. Syndr. 47(1), 36–49 (2008).
   PubMedGoogle Scholar
• Mira JA, Gutiérrez-Valencia A, Gil Ide L et al. Efficacy and safety of pegylated interferon plus ribavirin in HIV and hepatitis C virus-coinfected patients with advanced immunosuppression. Clin. Infect. Dis. 49(8), e84–e91 (2009).
   Google Scholar
• Ge D, Fellay J, Thompson AJ et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461(7262), 399–401 (2009).
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Nishida N, Sugiyama M et al. Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C. Nat. Genet. 41(10), 1105–1109 (2009).
   PubMed Web of Science ®Google Scholar
• McCarthy JJ, Li JH, Thompson A et al. Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin. Gastroenterology 138(7), 2307–2314 (2010).
   PubMed Web of Science ®Google Scholar
• Suppiah V, Moldovan M, Ahlenstiel G et al. IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy. Nat. Genet. 41(10), 1100–1104 (2009).
   PubMed Web of Science ®Google Scholar
• Romero-Gomez M, Eslam M, Ruiz A, Maraver M. Genes and hepatitis C: susceptibility, fibrosis progression and response to treatment. Liver Int. 31(4), 443–460 (2011).
   PubMed Web of Science ®Google Scholar
• Chen Y, Xu HX, Wang LJ, Liu XX, Mahato RI, Zhao YR. Meta-analysis: IL28B polymorphisms predict sustained viral response in HCV patients treated with pegylated interferon-a and ribavirin. Aliment. Pharmacol. Ther. 36(2), 91–103 (2012).
   PubMed Web of Science ®Google Scholar
• Dayyeh BK, Gupta N, Sherman KE, de Bakker PI, Chung RT; AIDS Clinical Trials Group A5178 Study Team. IL28B alleles exert an additive dose effect when applied to HCV-HIV coinfected persons undergoing peginterferon and ribavirin therapy. PLoS One 6(10), e25753 (2011).
   Web of Science ®Google Scholar
• Payer BA, Reiberger T, Aberle J et al. Vienna HIV-HCV study group. IL28B and interferon-γ inducible protein 10 for prediction of rapid virologic response and sustained virologic response in HIV-HCV-coinfected patients. Eur. J. Clin. Invest. 42(6), 599–606 (2012).
   PubMed Web of Science ®Google Scholar
• Qu J, Zhang Q, Li Y et al. The Tat protein of human immunodeficiency virus-1 enhances hepatitis C virus replication through interferon γ-inducible protein-10. BMC Immunol. 13, 15 (2012).
   PubMedGoogle Scholar
• Medrano J, Neukam K, Rallón N et al. Modeling the probability of sustained virological response to therapy with pegylated interferon plus ribavirin in patients coinfected with hepatitis C virus and HIV. Clin. Infect. Dis. 51(10), 1209–1216 (2010).
   PubMed Web of Science ®Google Scholar
• Suppiah V, Gaudieri S, Armstrong NJ et al.; International Hepatitis C Genetics Consortium (IHCGC). IL28B, HLA-C, and KIR variants additively predict response to therapy in chronic hepatitis C virus infection in a European Cohort: a cross-sectional study. PLoS Med. 8(9), e1001092 (2011).
   Google Scholar
• Van den Eynde E, Crespo M, Esteban JI et al. Response-guided therapy for chronic hepatitis C virus infection in patients coinfected with HIV: a pilot trial. Clin. Infect. Dis. 48(8), 1152–1159 (2009).
   PubMed Web of Science ®Google Scholar
• Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB; American Association for Study of Liver Diseases. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 54(4), 1433–1444 (2011).
   PubMed Web of Science ®Google Scholar
• Deming P, McNicholl IR. Coinfection with human immunodeficiency virus and hepatitis C virus: challenges and therapeutic advances. Insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy 31(4), 357–368 (2011).
   PubMed Web of Science ®Google Scholar
• Osinusi A, Rasimas JJ, Bishop R et al. HIV/Hepatitis C virus-coinfected virologic responders to pegylated interferon and ribavirin therapy more frequently incur interferon-related adverse events than nonresponders do. J. Acquir. Immune Defic. Syndr. 53(3), 357–363 (2010).
   PubMedGoogle Scholar
• Bhattacharya D, Umbleja T, Carrat F et al. Women experience higher rates of adverse events during hepatitis C virus therapy in HIV infection: a meta-analysis. J. Acquir. Immune Defic. Syndr. 55(2), 170–175 (2010).
   PubMedGoogle Scholar
• de Vera ME, Dvorchik I, Tom K et al. Survival of liver transplant patients coinfected with HIV and HCV is adversely impacted by recurrent hepatitis C. Am. J. Transplant. 6(12), 2983–2993 (2006).
   PubMed Web of Science ®Google Scholar
• Pineda JA, Romero-Gómez M, Díaz-García F et al. Grupo Andaluz para el Estudio de las Enfermedades Infecciosas; Grupo Andaluz para el Estudio del Hígado. HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis. Hepatology 41(4), 779–789 (2005).
   PubMed Web of Science ®Google Scholar
• Huprikar S. Solid organ transplantation in HIV-infected individuals: an update. Rev. Med. Virol. 19(6), 317–323 (2009).
   PubMedGoogle Scholar
• Roland ME, Stock PG. Liver transplantation in HIV-infected recipients. Semin. Liver Dis. 26(3), 273–284 (2006).
   PubMed Web of Science ®Google Scholar
• Miró JM, Torre-Cisnero J, Moreno A et al. GESIDA/GESITRA-SEIMC, PNS and ONT consensus document on solid organ transplant (SOT) in HIV-infected patients in Spain (March, 2005). Enferm. Infecc. Microbiol. Clin. 23(6), 353–362 (2005).
   PubMedGoogle Scholar
• Samuel D, Duclos Vallee JC, Teicher E, Vittecoq D. Liver transplantation in patients with HIV infection. J. Hepatol. 39(1), 3–6 (2003).
   PubMedGoogle Scholar
• Sugawara Y, Tamura S, Kokudo N. Liver transplantation in HCV/HIV positive patients. World J. Gastrointest. Surg. 3(2), 21–28 (2011).
   PubMedGoogle Scholar
• Sulkowski M, Pol S, Cooper C et al. Boceprevir plus peginterferon/ribavirin for the treatment of HCV/HIV co-infected patients: interim on-treatment results. Presented at: 49th Annual Meeting of the Infectious Diseases Society of America. Boston, MA, USA, 20–23 October 2011.
   Google Scholar
• Sulkowski M, Pol S, Cooper C et al. Boceprevir plus peginterferon/ribavirin for the treatment of HCV/HIV co-infected patients. Presented at: 19th Conference on Retroviruses and Opportunistic Infections. Seattle, WA, USA, 5–8 March 2012.
   Google Scholar
• Sulkowski M, Dieterich DT, Sherman KE et al. Interim analysis of a phase IIa double-blind study of TVR in combination with peg-IFN-a2a and RBV in HIV/HCV co-infected patients. Presented at: 18th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA, 27 February–2 March 2011.
   Google Scholar
• Sherman KE, Rockstroh JK, Dieterich DT et al. Telaprevir in combination with peginterferon α-2a/ribavirin in HCV/HIV coinfected patients: a 24-week treatment interim analysis. Presented at: 62nd Annual Meeting of the American Association for the Study of Liver Disease. San Francisco, CA, USA, 4–8 November 2011.
   Google Scholar
• Dietrich D, Soriano V, Sherman K et al. Telaprevir in combination with peginterferon alfa-2a/ribavirin in HCV/HIV co-infected patients: SVR12 interim analysis. Presented at: 19th Conference on Retroviruses and Opportunistic Infections. Seattle, WA, USA, 5–8 March 2012.
   Google Scholar
• Telaprevir (package insert) INCIVEK™. Vertex Pharmaceuticals Inc., MA, USA (2011).
   Google Scholar
• Boceprevir (package insert) VICTRELIS™. Merck & Co., Inc., NJ, USA (2011).
   Google Scholar
• Garg V, Kauffman RS, Beumont M, van Heeswijk. Drug interaction profile of Telaprevir. Presented at: HEP DART 2011. Koloa, HI, USA, 4–8 December 2011.
   Google Scholar
• Van Heeswijk R, Vandevoorde A, Boogaerts G et al. Pharmacokinetic interactions between ARV agents and the investigational HCV protease inhibitor TVR in healthy volunteers. Presented at: 18th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA, 27 February–2 March 2011.
   Google Scholar
• van Heeswijk R, Garg V, Boogaerts G et al. The pharmacokinetic interaction between telaprevir and raltegravir in healthy volunteers. Presented at: 51st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA, 17–20 September 2011.
   Google Scholar
• Kasserra C, Hughes E, Treitel M, Gupta S, O’Mara E. Clinical pharmacology of BOC: metabolism, excretion, and drug-drug interactions. Presented at: 18th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA, 27 February–2 March 2011.
   Google Scholar
• Hulskotte EGJ, Feng HP, Xuan F et al. Pharmacokinetic interaction between the HCV protease inhibitor boceprevir and ritonavir-boosted HIV-1 protease inhibitors atazanavir, lopinavir, and darunavir. Presented at: 19th Conference on Retroviruses and Opportunistic Infections. Seattle, WA, USA, 5–8 March 2012.
   Google Scholar
• De Kanter C, Blonk MI, Colbers A et al. Influence of the HCV protease inhibitor Boceprevir on the pharmacokinetics of the HIV integrase inhibitor raltegravir. Presented at: 19th Conference on Retroviruses and Opportunistic Infections. Seattle, WA, USA, 5–8 March 2012.
   Google Scholar
• Thomas DL, Bartlett JG, Peters MG, Sherman KE, Sulkowski MS, Pham PA. Provisional guidance on the use of hepatitis C virus protease inhibitors for treatment of hepatitis C in HIV-infected persons. Clin. Infect. Dis. 54(7), 979–983 (2012).
   PubMedGoogle Scholar
• Sherman KE, Fleischer R, Laessig K, Murray J, Tauber W, Birnkrant D; FDA Antiviral Products Advisory Committee. Development of novel agents for the treatment of chronic hepatitis C infection: Summary of the FDA Antiviral Products Advisory Committee recommendations. Hepatology 46(6), 2014–2020 (2007).
   PubMed Web of Science ®Google Scholar
• Miller CD, El-Kholi R, Faragon JJ, Lodise TP. Prevalence and risk factors for clinically significant drug interactions with antiretroviral therapy. Pharmacotherapy 27(10), 1379–1386 (2007).
   PubMed Web of Science ®Google Scholar
• Rodríguez-Rosado R, García-Samaniego J, Soriano V. Hepatotoxicity after introduction of highly active antiretroviral therapy. AIDS 12(10), 1256 (1998).
   PubMed Web of Science ®Google Scholar